NURIX THERAPEUTICS, INC. Receivables, Net, Current
NURIX THERAPEUTICS, INC. (NRIX) had Receivables, Net, Current of $0 as of 2022-11-30, per its 10-K filed 2023-02-09.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:ReceivablesNetCurrent · last filed 2023-02-09
- 2022-11-30: Receivables, Net, Current $0.00.
- 2022-02-28: Receivables, Net, Current $6.00M.
- 2021-11-30: Receivables, Net, Current $6.00M.
| Period end | Receivables, Net, Current |
|---|---|
| 2022-11-30 | $0.00 10-K · filed 2023-02-09 |
| 2022-02-28 | $6.00M 10-Q · filed 2022-04-08 |
| 2021-11-30 | $6.00M 10-K · filed 2023-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |